



## Novel Treatments and Technologies Applied to Neuroblastoma

Guest Editor:

### Dr. Praveen Bhoopathi

1. Department of Human and Molecular Genetics, School of Medicine, Virginia Commonwealth University,

Richmond, VA 23298, USA

2. VCU Institute of Molecular Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA

Deadline for manuscript submissions:

**closed (20 April 2024)**

### Message from the Guest Editor

Neuroblastoma (NB) is a prevalent extracranial solid tumor that develops in children. Documenting abnormalities at the genome, epigenome, and transcriptome levels, our knowledge of the molecular characteristics of human NBs continues to advance. The MYCN transcriptional regulator is highly expressed in the neural crest and is amplified in high-risk malignancies. Studies on the biology of NB have enabled a more precise risk stratification strategy and a concomitant reduction in the number of cases requiring treatment. To enhance outcomes and survival rates in these high-risk patients, a multicomponent therapeutic approach is required. Clinical staging of the disease and assessment of the associated risks based on biological, clinical, surgical, and pathological criteria are of the utmost importance for determining prognosis and planning effective therapeutic strategies. These reviews will examine the staging of neuroblastoma (NB), as well as the disease's biological and genetic characteristics, and several current therapies, including targeted chemotherapy delivery, novel radiation therapy, and immunotherapy for NB.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)